ElectroWire’s LightningWire Transseptal Puncture System Receives FDA Clearance

July 16, 2026—ElectroWire Medical announced that the FDA has granted 510(k) clearance for its LightningWire transseptal puncture system, which is indicated to create an atrial septal defect in the heart, whereby various cardiovascular catheters are introduced. The company is beginning immediate commercialization of the LightningWire system with a limited market release.

According to the company, the LightningWire system combines an electrosurgical guidewire with a dedicated activation cable to simplify procedures using preferred transseptal introducers and existing electrosurgical generators. The device’s insulation design is intended to optimize electrosurgical performance and mechanical properties along the length of the wire.

ElectroWire stated that the device’s distal insulation allows transseptal puncture at low power settings. It features a 0.032-inch labeled diameter that facilitates broad compatibility with various transseptal devices. Additionally, the stiffness of the LightningWire supports efficient transseptal delivery of therapy devices.

The LightningWire technology is available for use in the transseptal access systems procedures, including catheter ablation of atrial fibrillation, left atrial appendage occlusion, and transcatheter mitral valve repair and replacement, noted the company.

James Stewart, MD, commented in the company’s press release, “The ability to cross the septum in a precise location using the transseptal catheter of my choice and then deliver bulky equipment into the left side of the heart should streamline our left-sided procedures tremendously.” Dr. Stewart is a structural interventional cardiologist at Piedmont Atlanta’s Marcus Heart Valve Center, in Atlanta, Georgia.

William Brabham, MD, added, “Safe, effective, and efficient transseptal access is critical in the electrophysiology space. LightningWire meets all of these needs in a versatile device that can be used across industry platforms. It also has the potential to add cost savings for health systems as the economics of these important procedures evolve.” Dr. Brabham is Director of Cardiac Electrophysiology at Lexington Medical Center in Columbia, South Carolina.